Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.

Melosky, B; Agulnik, J; Albadine, R; Banerji, S; Bebb, D G; Bethune, D; Blais, N; Butts, C; Cheema, P; Cheung, P; Cohen, V; Deschenes, J; Ionescu, D N; Juergens, R; Kamel-Reid, S; Laurie, S A; Liu, G; Morzycki, W; Tsao, M S; Xu, Z; Hirsh, V

Melosky, B; Agulnik, J; Albadine, R; Banerji, S; Bebb, D G; Bethune, D; Blais, N; Butts, C; Cheema, P; Cheung, P; Cohen, V; Deschenes, J; Ionescu, D N; Juergens, R; Kamel-Reid, S; Laurie, S A; Liu, G; Morzycki, W; Tsao, M S; Xu, Z; Hirsh, V.

Afiliación

Melosky B; British Columbia: BC Cancer Agency, Vancouver Centre, Vancouver, BC (Melosky, Ionescu);
Agulnik J; Quebec: Jewish General Hospital, McGill University, Montreal, QC (Agulnik); chum -Hôpital St-Luc, Montreal, QC (Albadine); chum -Hôpital Notre-Dame, Montreal, QC (Blais); Royal Victoria Hospital, Montreal, QC (Hirsh); Segal Cancer Centre and Sir Mortimer B. Davis Jewish General Hospital, Montreal, Q
Albadine R; Quebec: Jewish General Hospital, McGill University, Montreal, QC (Agulnik); chum -Hôpital St-Luc, Montreal, QC (Albadine); chum -Hôpital Notre-Dame, Montreal, QC (Blais); Royal Victoria Hospital, Montreal, QC (Hirsh); Segal Cancer Centre and Sir Mortimer B. Davis Jewish General Hospital, Montreal, Q
Banerji S; Manitoba: CancerCare Manitoba and University of Manitoba, Winnipeg, MB (Banerji);
Bebb DG; Alberta: Tom Baker Cancer Centre, Calgary, AB (Bebb); Cross Cancer Institute and University of Alberta, Edmonton, AB (Butts, Deschenes);
Bethune D; Nova Scotia: QEII Health Sciences Centre, Halifax, NS (Bethune, Morzycki, Xu);
Blais N; Quebec: Jewish General Hospital, McGill University, Montreal, QC (Agulnik); chum -Hôpital St-Luc, Montreal, QC (Albadine); chum -Hôpital Notre-Dame, Montreal, QC (Blais); Royal Victoria Hospital, Montreal, QC (Hirsh); Segal Cancer Centre and Sir Mortimer B. Davis Jewish General Hospital, Montreal, Q
Butts C; Alberta: Tom Baker Cancer Centre, Calgary, AB (Bebb); Cross Cancer Institute and University of Alberta, Edmonton, AB (Butts, Deschenes);
Cheema P; Ontario: Sunnybrook Odette Cancer Centre, Toronto, ON (Cheema, Cheung); Juravinski Cancer Centre, Hamilton, ON (Juergens); University Health Network, Princess Margaret Cancer Centre, Toronto, ON (Kamel-Reid, Liu, Tsao); The Ottawa Hospital Cancer Centre, Ottawa, ON (Laurie).
Cheung P; Ontario: Sunnybrook Odette Cancer Centre, Toronto, ON (Cheema, Cheung); Juravinski Cancer Centre, Hamilton, ON (Juergens); University Health Network, Princess Margaret Cancer Centre, Toronto, ON (Kamel-Reid, Liu, Tsao); The Ottawa Hospital Cancer Centre, Ottawa, ON (Laurie).
Cohen V; Quebec: Jewish General Hospital, McGill University, Montreal, QC (Agulnik); chum -Hôpital St-Luc, Montreal, QC (Albadine); chum -Hôpital Notre-Dame, Montreal, QC (Blais); Royal Victoria Hospital, Montreal, QC (Hirsh); Segal Cancer Centre and Sir Mortimer B. Davis Jewish General Hospital, Montreal, Q
Deschenes J; Alberta: Tom Baker Cancer Centre, Calgary, AB (Bebb); Cross Cancer Institute and University of Alberta, Edmonton, AB (Butts, Deschenes);
Ionescu DN; British Columbia: BC Cancer Agency, Vancouver Centre, Vancouver, BC (Melosky, Ionescu);
Juergens R; Ontario: Sunnybrook Odette Cancer Centre, Toronto, ON (Cheema, Cheung); Juravinski Cancer Centre, Hamilton, ON (Juergens); University Health Network, Princess Margaret Cancer Centre, Toronto, ON (Kamel-Reid, Liu, Tsao); The Ottawa Hospital Cancer Centre, Ottawa, ON (Laurie).
Kamel-Reid S; Ontario: Sunnybrook Odette Cancer Centre, Toronto, ON (Cheema, Cheung); Juravinski Cancer Centre, Hamilton, ON (Juergens); University Health Network, Princess Margaret Cancer Centre, Toronto, ON (Kamel-Reid, Liu, Tsao); The Ottawa Hospital Cancer Centre, Ottawa, ON (Laurie).
Laurie SA; British Columbia: BC Cancer Agency, Vancouver Centre, Vancouver, BC (Melosky, Ionescu);
Liu G; British Columbia: BC Cancer Agency, Vancouver Centre, Vancouver, BC (Melosky, Ionescu);
Morzycki W; Nova Scotia: QEII Health Sciences Centre, Halifax, NS (Bethune, Morzycki, Xu);
Tsao MS; Ontario: Sunnybrook Odette Cancer Centre, Toronto, ON (Cheema, Cheung); Juravinski Cancer Centre, Hamilton, ON (Juergens); University Health Network, Princess Margaret Cancer Centre, Toronto, ON (Kamel-Reid, Liu, Tsao); The Ottawa Hospital Cancer Centre, Ottawa, ON (Laurie).
Xu Z; Nova Scotia: QEII Health Sciences Centre, Halifax, NS (Bethune, Morzycki, Xu);
Hirsh V; Quebec: Jewish General Hospital, McGill University, Montreal, QC (Agulnik); chum -Hôpital St-Luc, Montreal, QC (Albadine); chum -Hôpital Notre-Dame, Montreal, QC (Blais); Royal Victoria Hospital, Montreal, QC (Hirsh); Segal Cancer Centre and Sir Mortimer B. Davis Jewish General Hospital, Montreal, Q

Curr Oncol ; 23(3): 196-200, 2016 Jun.

Article en En | MEDLINE | ID: mdl-27330348

Palabras clave

ALK; anaplastic lymphoma kinase; molecular testing; non-small-cell lung cancer; targeted inhibition

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Curr Oncol Año: 2016 Tipo del documento: Article